Shares of Calyxt Inc. were soaring 12% Thursday in the gene-editing company’s debut on the Nasdaq. The company priced at $8 a share, the low-end of an already reduced price range, but shares were climbing above that Thursday, trading around $10.77. The company sold 7 million shares, an increased number of shares from previous IPO terms, to raise $56 million. Citigroup, Jefferies and Wells Fargo Securities were the lead underwriters on the offering.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News